Cannara Biotech (STU:8CB0) FCF Margin % : 11.70% (As of Aug. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cannara Biotech's Free Cash Flow for the three months ended in Aug. 2024 was €1.79 Mil. Cannara Biotech's Revenue for the three months ended in Aug. 2024 was €15.30 Mil. Therefore, Cannara Biotech's FCF Margin % for the quarter that ended in Aug. 2024 was 11.70%.

As of today, Cannara Biotech's current FCF Yield % is 4.64%.

The historical rank and industry rank for Cannara Biotech's FCF Margin % or its related term are showing as below:

STU:8CB0' s FCF Margin % Range Over the Past 10 Years
Min: -3728.41 Med: -194.87 Max: 3.93
Current: 3.32

During the past 7 years, the highest FCF Margin % of Cannara Biotech was 3.93%. The lowest was -3728.41%. And the median was -194.87%.

STU:8CB0's FCF Margin % is ranked better than
57.8% of 993 companies
in the Drug Manufacturers industry
Industry Median: 0.89 vs STU:8CB0: 3.32

Cannara Biotech FCF Margin % Historical Data

The historical data trend for Cannara Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech FCF Margin % Chart

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

FCF Margin %

Get a 7-Day Free Trial

-730.88

-194.86

-60.11

-6.93

3.93

Cannara Biotech Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
FCF Margin %	Get a 7-Day Free Trial															6.17	-12.42	6.18	6.35	11.70

Competitive Comparison of Cannara Biotech's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannara Biotech's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's FCF Margin % falls into.

Cannara Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cannara Biotech's FCF Margin for the fiscal year that ended in Aug. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Aug. 2024 )	/	Revenue (A: Aug. 2024 )
	=	2.135	/	54.299
	=	3.93 %

Cannara Biotech's FCF Margin for the quarter that ended in Aug. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Aug. 2024 )	/	Revenue (Q: Aug. 2024 )
	=	1.79	/	15.301
	=	11.70 %

Cannara Biotech FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (STU:8CB0) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

LOVFF:USA LOVE:Canada

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

Cannara Biotech Headlines

No Headlines